Editor's Pick Jan 4, 2023 Absent Resolution on FDA's LDT Oversight in 2022, Some Payors Began Advancing Their Own Requirements Premium Nov 30, 2022 Bladder Cancer Genomic Landscape Study Aims to Engender New Biomarker-Guided Therapies Premium Nov 8, 2022 Tests to Guide PARP Inhibitors Emerge as New Focus for Public-Private Harmonization Effort Premium Nov 1, 2022 Myriad Genetics to Submit Hereditary Cancer Risk Variants to ClinVar in 2023 Premium Oct 31, 2022 Angle Finalizes Plans for First Clinical CTC Test in Ovarian Cancer Premium Oct 19, 2022 Veto of California Bill Mandating Payor Coverage of Biomarker Tests Sparks Stakeholder Debate Premium Oct 17, 2022 Polygenic Risk Scores Could Refine Breast Cancer Screening Recommendations Premium Oct 4, 2022 Nonprofit's Efforts With Payors to Assess NGS Labs' Variant Interpretations Spark Debate Premium Oct 3, 2022 Highmark Asks Labs for Additional Validation Data on Cancer NGS Tests; Will Other Insurers Follow? Premium Sep 7, 2022 Larger Liquid Biopsy Panels Loom, But Patient Benefit Still Uncertain Premium Aug 18, 2022 Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change Premium Aug 8, 2022 CAP Weighs in on dMMR, MSI Assays for Immunotherapy Patient Selection Premium Jul 22, 2022 Lung Cancer MRD Study Bolsters Validity Evidence, Suggests Longitudinal Test Cutoff Premium Jun 22, 2022 Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer Premium Jun 15, 2022 Estimated Total Tumor mRNA Predicts Cancer Outcomes, Study Shows Premium Jun 8, 2022 New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur Premium May 20, 2022 MSK Starts Offering Pediatric Cancer Patients Whole-Genome, Transcriptome Sequencing Premium May 20, 2022 Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests Apr 8, 2022 Tempus Sets Sights on Pathology Market With New Informatics, Research Network Premium Jan 19, 2022 Protein-Based Liquid Biopsy Panel Assesses Tumor Microenvironment, Shows Prognostic Potential Premium Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
